Cargando…

Low dose rate brachytherapy using a tandem for cervical cancer

PURPOSE: To report the results of the Instituto Nacional de Cancerología México, of low dose rate brachytherapy for cervical cancer using only a tandem. A proportion of patients was treated with only a tandem, without ovoids, due to the distorted anatomy because of the tumour or previous external ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Javier, Aguirre Mendez, Poitevin-Chacón, Adela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086492/
https://www.ncbi.nlm.nih.gov/pubmed/28050178
_version_ 1782463745740505088
author Javier, Aguirre Mendez
Poitevin-Chacón, Adela
author_facet Javier, Aguirre Mendez
Poitevin-Chacón, Adela
author_sort Javier, Aguirre Mendez
collection PubMed
description PURPOSE: To report the results of the Instituto Nacional de Cancerología México, of low dose rate brachytherapy for cervical cancer using only a tandem. A proportion of patients was treated with only a tandem, without ovoids, due to the distorted anatomy because of the tumour or previous external radiation, or sometimes due to physician preference. MATERIAL AND METHODS: We report the results of 120 patients treated only with a tandem and the impact of this treatment on local control and survival from January 2005 to December 2006. The frequency of FIGO stage was: IIB 47%, IIIB 34%, IIA 9%, IIIA 4%, IB2 3% and IB1 3%. The median overall treatment time was 12 weeks. The value of the external beam radiation dose was 50-50.4 Gy in all patients and the value of the brachytherapy dose was 30 Gy given to point A. RESULTS: Complete clinical response was 83% at the end of brachytherapy. Time to recurrence and frequency were: IB1 – 17 months (20%), IB2 – none, IIA – 8 months (8.3%), IIB – 11 months (40%) and IIIB – 14 months (25%). 10.8% of patients had a persistent tumour, 3.3% had progression during treatment in stage IIB. Survival in months was 26 months for stage IB1, 30 for IB2, 25 for IIA, 28 for IIB, 27 for IIIA and 24 for IIIB. 25% of patients died during follow-up. CONCLUSIONS: These preliminary results suggest that there is no significant difference between the treatment with brachytherapy using a tandem and ovoids or a tandem alone.
format Online
Article
Text
id pubmed-5086492
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-50864922017-01-03 Low dose rate brachytherapy using a tandem for cervical cancer Javier, Aguirre Mendez Poitevin-Chacón, Adela J Contemp Brachytherapy Original Article PURPOSE: To report the results of the Instituto Nacional de Cancerología México, of low dose rate brachytherapy for cervical cancer using only a tandem. A proportion of patients was treated with only a tandem, without ovoids, due to the distorted anatomy because of the tumour or previous external radiation, or sometimes due to physician preference. MATERIAL AND METHODS: We report the results of 120 patients treated only with a tandem and the impact of this treatment on local control and survival from January 2005 to December 2006. The frequency of FIGO stage was: IIB 47%, IIIB 34%, IIA 9%, IIIA 4%, IB2 3% and IB1 3%. The median overall treatment time was 12 weeks. The value of the external beam radiation dose was 50-50.4 Gy in all patients and the value of the brachytherapy dose was 30 Gy given to point A. RESULTS: Complete clinical response was 83% at the end of brachytherapy. Time to recurrence and frequency were: IB1 – 17 months (20%), IB2 – none, IIA – 8 months (8.3%), IIB – 11 months (40%) and IIIB – 14 months (25%). 10.8% of patients had a persistent tumour, 3.3% had progression during treatment in stage IIB. Survival in months was 26 months for stage IB1, 30 for IB2, 25 for IIA, 28 for IIB, 27 for IIIA and 24 for IIIB. 25% of patients died during follow-up. CONCLUSIONS: These preliminary results suggest that there is no significant difference between the treatment with brachytherapy using a tandem and ovoids or a tandem alone. Termedia Publishing House 2010-01-13 2009-12 /pmc/articles/PMC5086492/ /pubmed/28050178 Text en Copyright: © 2010 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Article
Javier, Aguirre Mendez
Poitevin-Chacón, Adela
Low dose rate brachytherapy using a tandem for cervical cancer
title Low dose rate brachytherapy using a tandem for cervical cancer
title_full Low dose rate brachytherapy using a tandem for cervical cancer
title_fullStr Low dose rate brachytherapy using a tandem for cervical cancer
title_full_unstemmed Low dose rate brachytherapy using a tandem for cervical cancer
title_short Low dose rate brachytherapy using a tandem for cervical cancer
title_sort low dose rate brachytherapy using a tandem for cervical cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086492/
https://www.ncbi.nlm.nih.gov/pubmed/28050178
work_keys_str_mv AT javieraguirremendez lowdoseratebrachytherapyusingatandemforcervicalcancer
AT poitevinchaconadela lowdoseratebrachytherapyusingatandemforcervicalcancer